Company Description
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Our goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (“NBD1”).
We are conducting ongoing Phase 1 trials of our two highly potent NBD1 stabilizers and developing a portfolio of complementary CFTR modulators designed to work synergistically with our NBD1 stabilizers to improve CFTR function, as seen in preclinical models.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Michael Cloonan |
Contact Details
Address: 21 Hickory Drive, Suite 500 Waltham, MA 02451 United States | |
| Phone | (617) 819-2020 |
| Website | sionnatx.com |
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002036042 |
Key Executives
| Name | Position |
|---|---|
| Michael Cloonan, M.B.A. | Chief Executive Officer, President and Director |
| Charlotte McKee, M.D. | Chief Medical Officer |
| Elena Ridloff, C.F.A. | Chief Financial Officer and Head of Corporate Development |
| Paul Clancy, M.B.A. | Chairperson of the Board |
| Bruce Booth, D.Phil. | Director |
| H. Edward Fleming, Jr., M.D. | Director |
| Lucian Iancovici, M.D. | Director |
| Joshua Resnick, M.D., M.B.A. | Director |
| Marcella Kuhlman Ruddy, M.D. | Director |
| Laurie Stelzer, M.B.A. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 17, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Nov 26, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 12, 2024 | DRS | [Cover] Draft Registration Statement |